Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
663-01-013 ISMRM Abstract

A Study on Multi-parametric MRI Imaging for Predicting Prognosis in Patients with Advanced Chronic Liver Disease

Primary: Body - Liver
Secondary: Analysis Methods - Generative Models
663-01-013 · Diffusion MRI, Iron Quantification, and Steatosis in Human and Preclinical Studies · Thursday, 14 May, 8:30 AM–9:25 AM · Digital Posters Row D
Keywords: Magnetic Resonance Imaging (MRI) Prognosis Gd-EOB-DTPA Advanced chronic liver disease Nomogram
Accepted
Xinya Gao 1, Dandan Chen2, Xueqin Zhang2, Xiance Zhao3, Sicong Huang3,4
1Nantong University, Nantong, China
2Nantong Third People’s Hospital, Nantong, China
3Clinical and Technical Support, Philips Healthcare (Beijing), Beijing, China
4Philips Healthcare (Beijing), Beijing, China
Presenting Author: Xinya Gao

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. García-Pagán JC, Saffo S, Mandorfer M, et al. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep, 2020, 2(4):100122.
2. Bastati N, Beer L, Mandorfer M, et al. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease? Radiology, 2020, 294(1):98-107.
3. Yang W, Kim JE, Choi HC, et al. T2 mapping in gadoxetic acid-enhanced MRI: utility for predicting decompensation and death in cirrhosis. Eur Radiol, 2021, 31(11):8376-8387.
4. Liu C, Shen Z, Ma H, et al. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. Eur Radiol, 2022, 32(5):3006-3015.
5. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol, 2022, 18(1):55-66.
6. Bastati N, Beer L, Ba-Ssalamah A, et al. Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. J Hepatol. 2022;77(4):1005-1013.
7. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18(1):55-66.
8. Hamoud AR, Weaver L, Stec DE, et al. Bilirubin in the Liver-Gut Signaling Axis. Trends Endocrinol Metab. 2018;29(3):140-150.
9. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol, 2022, 18(1):55-66.
10. Ajmera V, Park CC, Caussy C, et al. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 155(2):307-310.e2.
11. Wong F, Reddy KR, O'Leary JG, et al. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transpl, 2019, 25(6):870-880.
12. Lee HJ, Hong SB, Lee NK, et al. Validation of functional liver imaging scores (FLIS) derived from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Child-Pugh score and FLIS. Eur Radiol, 2021, 31(11):8606-8614.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/663-01-013